Biopharma company developing affinity enhanced T cell receptor (TCR) engineered T cells to treat hematologic and solid tumor cancers.

Sectors
Healthcare
Life Sciences
First Invested
2014
Early
Company Status
IPO/Public
NASDAQ: ADAP
Board Members
Ali Behbahani, MD